Today is an important day for the sector. We are at very long term support (the 200 week MA) that has rarely been breached (occasionally but never in a sustained.
We are getting what I suspect is a dead cat bounce after the trouncing yesterday. The recent lows need to hold but there really seems to be nothing in terms.
In light of slow drug launches and disappointing sales, there is a growing chorus of voices saying the antibiotics drug market is broken; that the government must step in to.
The midterm elections are over and now we have a couple hour break before the 2020 presidential campaigning begins. The split congress is likely positive for the markets as they.
We are entering the heart of the SMID earning season and while it could have an impact on the individual stock, it usually does not have major impacts more broadly..
Back in August I published my first deep dive report “Bellus – David vs. Goliath Can BLU Deliver A Better Chronic Cough Drug Than Merck?” (Link) about Bellus Health (BLU.TO).
Yesterday I wondered if the sector was bottoming and evidence is building that we are bottoming. We still need to string some green days together and see stocks react positively.
The First time I met Aptose Biosciences (APTO) was at the Bloom-Burton conference in Toronto back in May 2018 following the request of several Chimera Research Group (CRG) subscribers. They.
Is the sector starting to bottom? It certainly does not feel like it as every gain is followed by more selling. No move higher seems to have any staying power..
Yesterday was brutal and there is really little to say about it as we are clearly in the middle of a massive correction if not outright bear market. I suspect.
It is unfortunate that the earnings weeks comes as the market seems to want to collapse. Industrial earnings are finally seeing the impact of the trade policies and now apparently.
This should not be week of no news as we have the ESMO data to digest as well as a number of large cap earnings to work through. Unless there.
Yesterday was obviously a great day for the sector with everything higher and by a lot. It is not stunning to see some pullback from that move but if there.
Chimera Research Group: What sets Briacell apart from other immuno-oncology approaches? Dr. William V. Williams, President and CEO of Briacell: Briacell is developing a novel cancer immunotherapy based on a.
Tell me if you heard this story before. Merger Monday and nothing happens in biotech. We have essentially run out of excuses as it was the political uncertainty and then.
I do not think there is much to say today outside of the obvious. The market is not looking good and we seem to be entering (or in the midst).
Yesterday was brutal to say the least. There really was nothing to like about it. The XBI seems to have broken below its range and the IBB is rushing to.
Yesterday 10/04, at 7:00 am ET, Sarepta Therapeutics (SRPT) with Dr. Mendell released the biopsy data from the fourth patient including full 4 patients “Functional Data” from Argentina at #WMS2018.
Tomorrow 10/04, at 7:00 am ET, Sarepta Therapeutics (SRPT) with Dr. Mendell are hosting a conference call from Argentina at #WMS2018 the 23rd International Annual World Muscle Society meeting, to.
Yet again another weekend is passed and yet again there are no major M&A. Yet again, it no longer seems to matter. A little different this morning is not a.
Yesterday was a little odd. It was generally a good day for the sector but a lot of companies had very large ranges for no apparent reason and on no.